UNCY — Unicycive Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSmall Cap
Brief: Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia
Unicycive tumbles as FDA flags manufacturing issues with kidney disease drug
Brief: Unicycive Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Unicycive Announces Q3 2024 Financial Results And Provides Business Update
Brief: Octagon Capital Advisors Lp Reports 9.1% Passive Stake In Unicycive Therapeutics Inc As Of Sept 30
Brief: Unicycive Therapeutics: Regained Compliance With Minimum Market Value Requirement - SEC Filing
Brief: Unicycive Therapeutics Submits New Drug Application to FDA for Oxylanthanum Carbonate
Brief: Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings From Pivotal Clinical Trial Of Oxylanthanum Carbonate (OLC)
Brief: Unicycive Therapeutics Files For Resale Of Up To 50.0 Million Shares By The Selling Stockholders - SEC Filing
India's Shilpa Medicare rises on positive results from drug trial
Brief: Unicycive Therapeutics Entered Into First Amendment To Manufacturing & Supply Agreement With Shilpa Medicare
Brief: Unicycive Therapeutics Achieves Study Objective In Oxylanthanum Carbonate Clinical Trial
Brief: Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors
U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
Unicycive Therapeutics rises on FDA's 'orphan' tag for kidney failure drug
Brief: Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by The FDA
Brief: Unicycive Therapeutics Issues Shareholder Letter To Highlight Corporate Progress And Key Upcoming Milestones